Physician profile
Dev Gerald Vaz
NPI 1174614804
$14,121.54
in general payments reported to CMS, 2019-2025
29 companies · $967 in 2025
The $967 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $998 · 2021: $423 · 2022: $811 · 2023: $1,536 · 2024: $8,928 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,740 · Food and Beverage: $3,615 · Travel and Lodging: $43.82 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,740.00 |
| Food and Beverage | $3,614.63 |
| Travel and Lodging | $43.82 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $7,939.11 | 2024 | Inpefa |
| Boston Scientific Corporation | $749.22 | 2019-2025 | Watchman Flx, Farapulse, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $647.12 | 2019-2025 | |
| Abbott Laboratories | $551.42 | 2020-2023 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $538.76 | 2020-2025 | Lifevest |
| Amgen INC. | $461.21 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $459.81 | 2021-2024 | Onyx Frontier, Symplicity G3, Corevalve Evolut R |
| Astrazeneca Pharmaceuticals Lp | $409.64 | 2020-2025 | Farxiga |
| Abiomed | $288.51 | 2021-2022 | |
| Philips North America LLC | $231.72 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Cvrx, INC. | $218.84 | 2023-2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $214.68 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic Vascular, INC. | $207.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.68 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $158.04 | 2022-2025 | Camzyos, Eliquis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149.54 | 2019-2024 | Xarelto |
| Pfizer INC. | $136.73 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $119.62 | 2023 | Magnetom Sola |
| Novo Nordisk INC | $84.03 | 2021-2024 | Wegovy |
| Astellas Pharma US INC | $69.99 | 2021 | |
| Amarin Pharma, INC. | $63.12 | 2019-2021 | |
| Atricure, INC. | $55.87 | 2024 | |
| Esperion Therapeutics, INC. | $45.49 | 2022-2025 | Nexletol |
| Kiniksa Pharmaceuticals, Ltd. | $33.82 | 2023 | Arcalyst |
| Kestra Medical Technology Services, INC. | $22.58 | 2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $18.24 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $17.10 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $15.41 | 2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $14.25 | 2023 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dev Vaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.